Joshua C Curtin
Overview
Explore the profile of Joshua C Curtin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1045
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Besse B, Goto K, Wang Y, Lee S, Marmarelis M, Ohe Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39755170
Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients...
2.
Lim S, Kang S, Kim D, Lee S, Synn C, Baek S, et al.
Cancer Res Commun
. 2024 Jun;
4(7):1748-1764.
PMID: 38916448
Significance: Amivantamab in synergy with pembrolizumab effectively eradicated EGFRHIGHMETHIGH tumor subcluster in the tumor microenvironment of head and neck squamous cell carcinoma and overcame resistance against anti-PD-1 immunotherapy.
3.
Cho B, Kim D, Spira A, Gomez J, Haura E, Kim S, et al.
Nat Med
. 2023 Sep;
29(10):2577-2585.
PMID: 37710001
Patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) often develop resistance to current standard third-generation EGFR tyrosine kinase inhibitors (TKIs); no targeted treatments are approved in...
4.
Park K, Sabari J, Haura E, Shu C, Spira A, Salgia R, et al.
Lung Cancer
. 2023 Mar;
178:166-171.
PMID: 36868177
Background: Amivantamab, a fully humanized EGFR-MET bispecific antibody, has antitumor activity in diverse EGFR- and MET-driven non-small cell lung cancer (NSCLC) and a safety profile consistent with associated on-target activities....
5.
Viteri S, Minchom A, Bazhenova L, Ou S, Bauml J, Shell S, et al.
Mol Oncol
. 2022 Oct;
17(2):230-237.
PMID: 36269676
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR-mutant nonsmall cell lung cancers. We analysed real-world datasets to determine the frequency of...
6.
Jatkoe T, Wang S, Odegaard J, Velasco Roth A, Osgood D, Martinez G, et al.
J Mol Diagn
. 2022 Aug;
24(11):1181-1188.
PMID: 35963523
Amivantamab, an epidermal growth factor receptor (EGFR)-c-Met bispecific antibody, targets activating/resistance EGFR mutations and MET mutations/amplifications. In the ongoing CHRYSALIS study (ClinicalTrials.gov Identifier: NCT02609776), amivantamab demonstrated antitumor activity in patients...
7.
Park K, Haura E, Leighl N, Mitchell P, Shu C, Girard N, et al.
J Clin Oncol
. 2021 Aug;
39(30):3391-3402.
PMID: 34339292
Purpose: Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor () exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with...
8.
Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K, et al.
Cancer Discov
. 2020 May;
10(8):1194-1209.
PMID: 32414908
exon 20 insertion driver mutations (Exon20ins) in non-small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR-MET, has shown preclinical...
9.
Curtin J, Lorenzi M
Oncotarget
. 2018 Nov;
9(78):34856.
PMID: 30410683
[This corrects the article DOI: 10.18632/oncotarget.191.].
10.
Curtin J
Expert Opin Drug Discov
. 2013 Jun;
8(9):1153-64.
PMID: 23768167
Introduction: Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, with > 1.2 million new cases and > 600,000 deaths per year. This complex disease is driven by...